Latest Insider Transactions at Genelux Corp (GNLX)
This section provides a real-time view of insider transactions for Genelux Corp (GNLX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GENELUX CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GENELUX CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 29
2024
|
Mary Mirabelli Director |
BUY
Open market or private purchase
|
Direct |
8,000
+39.1%
|
-
|
|
May 29
2024
|
John Thomas Director |
BUY
Open market or private purchase
|
Direct |
2,500
+0.53%
|
-
|
|
May 29
2024
|
John W Smither Director |
BUY
Open market or private purchase
|
Direct |
6,250
+32.18%
|
-
|
|
May 29
2024
|
James L Tyree Director |
BUY
Open market or private purchase
|
Direct |
6,250
+39.16%
|
-
|
|
May 29
2024
|
Lourie S. Zak Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
31,250
+50.0%
|
-
|
|
May 29
2024
|
Sean Ryder General Counsel |
BUY
Open market or private purchase
|
Direct |
10,000
+48.61%
|
-
|
|
May 29
2024
|
Ralph Smalling Head of Regulatory |
BUY
Open market or private purchase
|
Direct |
1,250
+8.58%
|
-
|
|
May 29
2024
|
Thomas Zindrick President and CEO |
BUY
Open market or private purchase
|
Indirect |
200,000
+50.0%
|
-
|
|
May 29
2024
|
Tony Yu SVP, Clinical Development |
BUY
Open market or private purchase
|
Direct |
2,500
+50.0%
|
-
|
|
May 15
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
17,094
-1.48%
|
$51,282
$3.66 P/Share
|
|
May 14
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
15,426
-1.32%
|
$46,278
$3.58 P/Share
|
|
May 13
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
3,446
-0.29%
|
$10,338
$3.62 P/Share
|
|
May 08
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
13,919
-1.17%
|
$41,757
$3.82 P/Share
|
|
May 07
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
6,025
-0.5%
|
$18,075
$3.67 P/Share
|
|
May 01
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
33,061
-2.69%
|
$99,183
$3.3 P/Share
|
|
Apr 30
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
20,535
-1.64%
|
$61,605
$3.12 P/Share
|
|
Apr 29
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
6,403
-0.51%
|
$19,209
$3.25 P/Share
|
|
Apr 24
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
8,064
-0.64%
|
$24,192
$3.5 P/Share
|
|
Apr 23
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
22,000
-1.71%
|
$66,000
$3.49 P/Share
|
|
Apr 22
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
14,331
-1.1%
|
$42,993
$3.53 P/Share
|
|
Apr 17
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
22,737
-1.72%
|
$68,211
$3.71 P/Share
|
|
Apr 16
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
48,683
-3.55%
|
$146,049
$3.53 P/Share
|
|
Mar 14
2024
|
Caroline Jewett Head of Quality |
BUY
Grant, award, or other acquisition
|
Direct |
3,612
+12.24%
|
-
|
|
Mar 14
2024
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,270
+28.93%
|
-
|
|
Mar 14
2024
|
Tony Yu SVP, Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
11,557
+39.48%
|
-
|
|
Mar 14
2024
|
Joseph Cappello Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,557
+35.55%
|
-
|
|
Mar 14
2024
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
2,107
+10.4%
|
-
|
|
Mar 14
2024
|
Lourie S. Zak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,852
+9.11%
|
-
|
|
Mar 14
2024
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
26,264
+34.35%
|
-
|
|
Feb 19
2024
|
Caroline Jewett Head of Quality |
BUY
Grant, award, or other acquisition
|
Direct |
1,143
+4.88%
|
-
|
|
Feb 19
2024
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,936
+17.85%
|
-
|
|
Feb 19
2024
|
Tony Yu SVP, Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,661
+37.27%
|
-
|
|
Feb 19
2024
|
Joseph Cappello Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,661
+28.04%
|
-
|
|
Feb 19
2024
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
616
+4.23%
|
-
|
|
Feb 19
2024
|
Lourie S. Zak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,220
+3.62%
|
-
|
|
Feb 19
2024
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,320
+26.59%
|
-
|
|
Dec 15
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
32,535
-91.08%
|
$422,955
$13.56 P/Share
|
|
Dec 13
2023
|
James L Tyree Director |
SELL
Open market or private sale
|
Direct |
9,000
-47.27%
|
$117,000
$13.32 P/Share
|
|
Dec 13
2023
|
John Thomas Director |
SELL
Open market or private sale
|
Direct |
9,000
-0.96%
|
$117,000
$13.58 P/Share
|
|
Dec 07
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
36,800
-53.08%
|
$404,800
$11.85 P/Share
|
|
Nov 21
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
18,665
-21.21%
|
$186,650
$10.26 P/Share
|
|
Nov 20
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
14,594
-14.23%
|
$160,534
$11.26 P/Share
|
|
Nov 17
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
3,541
-3.34%
|
$46,033
$13.04 P/Share
|
|
Oct 25
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
5,704
-0.41%
|
$108,376
$19.4 P/Share
|
|
Oct 24
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
5,200
-4.67%
|
$98,800
$19.11 P/Share
|
|
Oct 24
2023
|
Tony Yu SVP, Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+4.46%
|
$31,200
$6.0 P/Share
|
|
Oct 23
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
49,987
-3.5%
|
$949,753
$19.97 P/Share
|
|
Oct 16
2023
|
John Thomas Director |
SELL
Open market or private sale
|
Direct |
3,333
-0.35%
|
$66,660
$20.9 P/Share
|
|
Oct 10
2023
|
Tony Yu SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
5,200
-2.34%
|
$114,400
$22.43 P/Share
|
|
Oct 10
2023
|
Tony Yu SVP, Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+4.46%
|
$31,200
$6.0 P/Share
|